Det primære slutmål for effekt var i alle fire studier antallet af patienter i hver gruppe, som opnåede PASI 75 (dvs mindst 75% forbedring i Psorisis Arealet og på Severity Index scoren i forhold til baseline) efter 12 ugers behandling.
The primary efficacy endpoint in all four studies was the proportion of patients in each treatment group who achieved the PASI 75 (i. e., at least a 75% improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks.